Oniria (Zolpidem Tartrate)

Zolpidem tartrate, the active ingredient in Oniria, is a non‑benzodiazepine hypnotic presented as a tablet for oral use. It is indicated for the short‑term treatment of insomnia in adults. GNH USA supplies Oniria as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Oniria as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Zolpidem tartrate is used to manage sleep initiation problems within the broader category of insomnia disorders.

- Insomnia (sleep onset insomnia): Helps patients fall asleep more quickly. - Transient insomnia due to stress or jet‑lag: Provides short‑term relief of difficulty falling asleep. - Primary sleep disorder: Improves overall sleep latency in diagnosed primary insomnia.

Adverse reactions to zolpidem are reported across a range of frequencies.

Common Side Effects: - Drowsiness: Persistent sleepiness during waking hours. - Dizziness: Light‑headed sensation, especially when standing quickly. - Headache: Mild to moderate head pain. - Nausea: Stomach discomfort or urge to vomit. - Dry mouth: Reduced salivation. - Unpleasant taste: Metallic or bitter sensation in the mouth.

Serious or Rare Side Effects: - Complex sleep‑related behaviours: Sleepwalking, sleep‑driving or other activities while not fully awake. - Allergic reactions: Rash, itching, swelling, or difficulty breathing. - Depression or mood changes: Worsening depressive symptoms or new onset mood disturbances. - Hallucinations: Visual or auditory disturbances. - Suicidal thoughts: Emergence of suicidal ideation. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing zolpidem, clinicians should consider several safety aspects.

- Assess sleep disorder duration: Confirm that use is limited to short‑term therapy (typically ≤ 7 days). - Evaluate comorbid conditions: Review psychiatric, respiratory or hepatic disorders before initiating therapy. - Avoid alcohol: Concomitant alcohol use can amplify sedative effects and increase risk of respiratory depression. - Monitor for dependence: Watch for signs of tolerance, misuse or withdrawal with prolonged use. - Counsel on next‑day activities: Advise patients to ensure a full night’s sleep before driving or operating machinery. - Store at ambient temperature: Keep tablets in the original container, protect from moisture and heat.

Zolpidem may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Opioids: Combined use can increase risk of profound sedation and respiratory depression. - Central nervous system depressants: Concurrent benzodiazepines or barbiturates may cause excessive sedation. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): May raise zolpidem plasma concentrations.

Moderate Interactions (Monitor Closely): - Antidepressants (especially SSRIs): May augment sleep‑related side effects. - Antihistamines: Can enhance drowsiness. - Alcohol: Even moderate intake can intensify sedation and impair cognition.